| Issue Date | Title | Author(s) |
| Nov-2021 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) | Sun, Hui-Chuan; Zhou, Jian; Wang, Zheng; Liu, Xiufeng; Xie, Qing; Jia, Weidong; Zhao, Ming; Bi, Xinyu; Li, Gong; Bai, Xueli; Ji, Yuan; Xu, Li; Zhu, Xiao-Dong; Bai, Dousheng; Chen, Yajin; Chen, Yongjun; Dai, Chaoliu; Guo, Rongping; Guo, Wenzhi; Hao, Chunyi; Huang, Tao; Huang, Zhiyong; Li, Deyu; Li, Gang; Li, Tao; Li, Xiangcheng; Liang, Xiao; Liu, Jingfeng; Liu, Fubao; Lu, Shichun; Lu, Zheng; Lv, Weifu; Mao, Yilei; Shao, Guoliang; Shi, Yinghong; Song, Tianqiang; Tan, Guang; Tang, Yunqiang; Tao, Kaishan; Wan, Chidan; Wang, Guangyi; Wang, Lu; Wang, Shunxiang; Wen, Tianfu; Xing, Baocai; Xiang, Bangde; Yan, Sheng; Yang, Dinghua; Yin, Guowen; Yin, Tao; Yin, Zhenyu; Yu, Zhengping; Zhang, Bixiang; Zhang, Jialin; Zhang, Shuijun; Zhang, Ti; Zhang, Yamin; Zhang, Yubao; Zhang, Aibin; Zhao, Haitao; Zhou, Ledu; Zhang, Wu; Zhu, Zhenyu; Qin, Shukui; Shen, Feng; Cai, Xiujun; Teng, Gaojun; Cai, Jianqiang; Chen, Minshan; Li, Qiang; Liu, Lianxin; Wang, Weilin; Liang, Tingbo; Dong, Jiahong; Chen, Xiaoping; Wang, Xuehao; Zheng, Shusen; Fan, Jia |
| Jul-2023 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations | Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng |
| 2019 | Clinicopathological Outcomes and Prognosis of Elderly Patients (65Years) with Gastric Gastrointestinal Stromal Tumors (GISTs) Undergoing Curative-Intent Resection: a Multicenter Data Review | Yang, Zifeng; Feng, Xingyu; Zhang, Peng; Chen, Tao; Qiu, Haibo; Zhou, Yongjian; Du, Chunyan; Yin, Xiaonan; Pan, Fang; Zheng, Guoliang; Liu, Xiufeng; Huang, Changming; Zhou, Zhiwei; Li, Guoxin; Tao, Kaixiong; Li, Yong |
| 2019 | Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study | Zhang, Xinhua; Zhou, Ye; Wu, Xin; Nie, Mingming; Zhang, Bo; Zhou, Yongjian; Sun, Lifeng; Liu, Zimin; Liu, Xiufeng; Kou, Youwei; Wang, Yongpeng; Zhang, Yefan; Hao, Chunyi; Shen, Lin; Li, Jian |
| 20-May-2021 | Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients. | Tang, Bixia; Chi, Zhihong; Chen, Yingbo; Liu, Xiufeng; Wu, Di; Chen, Jing; Song, Xin; Wang, Weifeng; Dong, Lihou; Song, Haifeng; Wu, Hai; Qin, Shukui; Guo, Jun; Zhang, Xiaoshi; Yao, Sheng; Feng, Hui |
| Sep-2020 | A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood | Zhou, Ye; Zhang, Xinhua; Wu, Xiaojun; Zhou, Yongjian; Zhang, Bo; Liu, Xiufeng; Wu, Xin; Li, Yan; Shen, Lin; Li, Jian |
| 2019 | Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial. | Li, Jian; Zhou, Ye; Zhang, Xinhua; Wu, Xiaojun; Zhou, Yongjian; Liu, Xiufeng; Zhang, Bo; Wu, Xin; Lin, Shen |
| 15-Aug-2020 | Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial | Tang, Bixia; Chi, Zhihong; Chen, Yingbo; Liu, Xiufeng; Wu, Di; Chen, Jing; Song, Xin; Wang, Weifeng; Dong, Lihou; Song, Haifeng; Wu, Hai; Feng, Hui; Yao, Sheng; Qin, Shuikui; Zhang, Xiaoshi; Guo, Jun |
| 2018 | To compare the efficacy of sunitinib and imatinib following cytoreductive resection in GIST patients with progression on imatinib: A multi-center controlled study. | Zhang, Xinhua; Zhou, Ye; Wu, Xin; Nie, Mingming; Zhang, Bo; Zhou, Yongjian; Sun, Lifeng; Liu, Xiufeng; Liu, Zimin; Kou, Youwei; Wang, Yongpeng; Zhang, Yefan; Li, Jian; Shen, Lin |
| 2015 | Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma | Liu, Zhipeng; Liu, Xiufeng; Cao, Wenmin; Hua, Zi-Chun |
| 2019 | Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. | Park, Joon Oh; Feng, Yin-Hsun; Chen, Yen-Yang; Su, Wu-Chou; Oh, Do-Youn; Shen, Lin; Kim, Kyu-Pyo; Liu, Xiufeng; Bai, Yuxian; Liao, Huimin; Nie, Jing; Qing, Min; Ji, Qinmei; Li, Jiongyan; Zhao, Mianzhi; De Porre, Peter; Monga, Manish |
